by Clinical Neuropsychologist | Friday, June 28, 2024 | Dementia
Abstract Over the past decades, accumulating evidence suggests that the gut microbiome exerts a key role in Alzheimer’s disease (AD). The Alzheimer’s Association Workgroup is updating the diagnostic criteria for AD, which changed the profiles and...
by Clinical Neuropsychologist | Friday, June 28, 2024 | Dementia
Abstract INTRODUCTION Trisomy 21, or Down syndrome (DS), predisposes individuals to early-onset Alzheimer’s disease (AD). While monoclonal antibodies (mAbs) targeting amyloid are approved for older AD patients, their efficacy in DS remains unexplored. This study...
by Clinical Neuropsychologist | Friday, June 28, 2024 | Dementia
Abstract INTRODUCTION Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA) as a test for...
by Clinical Neuropsychologist | Friday, June 28, 2024 | Dementia
Abstract INTRODUCTION Primary age-related tauopathy (PART), often regarded as a minimally symptomatic pathology of old age, lacks comprehensive cohorts across various age groups. METHODS We examined PART prevalence and clinicopathologic features in 1589 forensic...
by Clinical Neuropsychologist | Friday, June 28, 2024 | Dementia
Abstract INTRODUCTION To investigate the role of a novel type of protein kinase C delta (PKCδ) in the neuroinflammation of Alzheimer’s disease (AD). METHODS We analyzed PKCδ and inflammatory cytokines levels in cerebrospinal fluid (CSF) of AD and normal...
